Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

Phase 3

Recruiting

• Conditions: HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer; ER-positive Breast Cancer
• Interventions: Drug: Elacestrant; Drug: Tamoxifen; Drug: Letrozole 2.5mg; Drug: Anastrozole 1mg; Drug: Exemestane 25 MG

• Registration Number: NCT05512364
• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary

This is an international, multi-center, randomised, open label, superiority phase III trial of elacestrant vs standard endocrine therapy in patients with ER+/HER2- breast cancer and ctDNA relapse.

During the ctDNA screening phase, patients will be tested at different timepoints to detect the presence of ctDNA in their blood.

Patients who are found to be ctDNA-positive and have no evidence of distant metastasis, will be randomised 1:1 between standard endocrine treatment (the same they were receiving when tested ctDNA positive) versus elacestrant, provided they meet all eligibility criteria. After completion of the protocol treatment period, treatment will be left at the discretion of the treating physician.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-08-22
• Study First Submitted QC: 2022-08-22
• Study First Posted: 2022-08-23
• Study Start: 2023-12-15
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-23
• Last Update Posted: 2024-01-24
• Primary Completion: 2028-07-01
• Study Completion: 2030-05-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 220

Inclusion Criteria

• ctDNA screening phase

  • Female or male patients with histologically confirmed ER positive (regardless of PR), HER2 negative breast cancer, according to local pathologist:

    • ER-positive defined as ≥ 10% of cells staining positive for ER
    • HER2-negative defined as a score of 0, 1+ by immunohistochemistry (IHC) or a negative in situ hybridization (ISH) based on single-probe average HER2 copy number, as per American Society of Clinical Oncology guidelines

  • Elevated risk of recurrence after definitive treatment for early breast cancer, defined as either:

    • Stage IIB or stage III disease according to the 8th edition of the UICC TNM classification and completion of adjuvant chemotherapy, OR
    • Completion of at least 4 cycles of neoadjuvant chemotherapy and residual tumour at surgery of ≥ 1cm (≥ypT1c) or axillary node + (ypN+)

  • Pre- or postmenopausal status (for female patients).

  • Age ≥18 years

  • Patients must have received at least 2 years and up to 7 years of ET

  • Previous adjuvant CDK4/6 inhibitor or PARP-inhibitor treatment is allowed if completed at least 12 months before registration

  • Patients with multifocal tumours are allowed provided all foci are biopsied and are ER-positive and HER2-negative as defined above

  • Available FFPE tumour block from the baseline biopsy or from surgical specimen or at least 10 slides of 10μm and a tumour cellularity of at least 25%. For patients with multifocal tumours, FFPE block or slides from the largest focus is required.

  • Written informed consent must be given according to ICH/GCP, and national/local regulations.

• Randomised phase

  • ctDNA positive according to the Signatera ctDNA assay

  • Absence of locoregional and/or metastatic disease, as investigated by:

    • Mammogram (unilateral in case of mastectomy; not required in patients having undergone bilateral mastectomy)
    • CT thorax and abdomen/pelvis with IV contrast. In case of any contra-indications (medical or regulatory): CT thorax without contrast + MRI abdomen/pelvis.
    • Technetium-99m bone scintigraphy

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

  • Adequate organ function

  • Women of childbearing potential (WOCBP) must have a negative highly sensitive serum or urine pregnancy test within 3 days prior to randomisation.

Exclusion Criteria

• ctDNA screening phase

  • Suspected recurrent disease or known conflicts with the inclusion and exclusion criteria for the randomised trial
  • Prior treatment with any SERD or investigational ER antagonist
  • Previous history of invasive breast cancer
  • Previous history of any other malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix . Patients who have been disease free for more than 5 years with low risk of relapse are allowed
  • Bilateral breast cancer
  • Participation in another clinical study, with the exception of the SURVIVE study Note: patients participating in interventional studies may participate once they enter the follow-up period of the study

• Randomised phase

  • Any unresolved toxic effect of prior therapies or surgical procedures of Grade ≥ 2 according to Common Terminology Criteria of Adverse Events (CTCAE) v5.0, with the exception of alopecia, peripheral neuropathy and other toxicities not considered a safety risk for the participant at investigator's discretion
  • Unable or unwilling to avoid prescription medications, over-the-counter medications, dietary/herbal supplements, and/or foods that are moderate/strong inhibitors or inducers of CYP3A4 activity
  • Known difficulty in tolerating oral medications or conditions which would impair absorption of oral medications
  • Any of the following cardiovascular disorders within 3 months before enrolment:
  • Child-Pugh Score greater than Class A
  • Uncontrolled significant active infections (≥ grade 3 according to CTCAE version 5), including active hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency Virus (HIV)
  • Coagulopathy or any history of coagulopathy within the past 6 months, including history of deep vein thrombosis or pulmonary embolism

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control arm	Letrozole 2.5mg	standard endocrine treatment - the same they were receiving at the time of ctDNA detection
Control arm	Anastrozole 1mg	standard endocrine treatment - the same they were receiving at the time of ctDNA detection
Control arm	Exemestane 25 MG	standard endocrine treatment - the same they were receiving at the time of ctDNA detection
Experimental arm	Elacestrant	elacestrant 400 mg/day orally once daily on a continuous dosing schedule
Control arm	Tamoxifen	standard endocrine treatment - the same they were receiving at the time of ctDNA detection

Primary Outcome Measures

Name	Time	Method
Distant metastasis free survival (DMFS)	5.2 years after first patient screened	DMFS defined as the time from randomisation until first distant metastatic recurrence or death from any cause, whichever occurs first

Secondary Outcome Measures

Name	Time	Method
ctDNA elimination rate at month 1	at month 1	defined as the proportion of randomised patients who had a negative ctDNA test result at month 1

Trial Locations

Locations (42)

Institut Jules Bordet; 🇧🇪 Anderlecht, Belgium

Pole Hospitalier Jolimont - Hopital Jolimont; 🇧🇪 Haine-Saint-Paul, Belgium

CHU Site Sainte-Elisabeth-UCL Namur; 🇧🇪 Namur, Belgium

AZ KLINA Brasschaat; 🇧🇪 Brasschaat, Belgium

AZ Turnhout - Campus Sint Elisabeth; 🇧🇪 Turnhout, Belgium

Cliniques Universitaires Saint-Luc; 🇧🇪 Brussels, Belgium

Beacon Hospital; 🇮🇪 Dublin, Ireland

AZ Delta - Campus Rumbeke; 🇧🇪 Roeselare, Belgium

AZ Delta Torhout; 🇧🇪 Torhout, Belgium

Mater Misericordia University Hospital; 🇮🇪 Dublin, Ireland

St James's Hospital; 🇮🇪 Dublin, Ireland

Grand Hopital de Charleroi - Site Notre Dame; 🇧🇪 Charleroi, Belgium

AZ Groeninge Kortrijk - Campus Kennedylaan; 🇧🇪 Kortrijk, Belgium

U.Z. Leuven - Campus Gasthuisberg; 🇧🇪 Leuven, Belgium

AZ Delta - Campus Menen; 🇧🇪 Menen, Belgium

Centre Hospitalier Regional Verviers; 🇧🇪 Verviers, Belgium

Centre de Radiotherapie Pierre Curie; 🇫🇷 Beuvry, France

CH de La Cote Basque - Saint Leon; 🇫🇷 Bayonne, France

Centre Hospitalier - Boulogne Sur Mer; 🇫🇷 Boulogne-sur-Mer, France

Centre d'Oncology Radiotherapie (ROC-37); 🇫🇷 Chambray-lès-Tours, France

CHU de Lyon - Hopital Femme Mere Enfant; 🇫🇷 Bron, France

CHU de Lyon - Hopital De La Croix Rousse; 🇫🇷 Lyon, France

Centre d'Oncologie de Gentilly; 🇫🇷 Nancy, France

CHU de Lyon - Hopital Lyon Sud; 🇫🇷 Pierre-Bénite, France

CHU de Toulouse - Institut Claudius Regaud - IUCT oncopole; 🇫🇷 Toulouse, France

MVM MbH -Onkologie UnterEms, Leer-Papenburg-Emden; 🇩🇪 Leer, Germany

Institut de Cancerologie Strasbourg Europe; 🇫🇷 Strasbourg, France

Universitaetsklinikum Ulm-Michelsberg; 🇩🇪 Ulm, Germany

Helios Klinikum Wuppertal - Klin. Univ. Witten / Herdecke; 🇩🇪 Wuppertal, Germany

University Hospital Waterford; 🇮🇪 Waterford, Ireland

Azienda Ospedaliera Papa Giovanni XXIII; 🇮🇹 Bergamo, Italy

Centro Di Riferimento Oncologico; 🇮🇹 Aviano, Italy

Azienda USL IRCCS Di Reggio Emilia Guastalla; 🇮🇹 Guastalla, Italy

Ospedale Alessandro Manzoni; 🇮🇹 Lecco, Italy

Azienda Ospedaliero-Universitaria Careggi; 🇮🇹 Firenze, Italy

Mater Salutis Hospital; 🇮🇹 Legnano, Italy

Cliniche Humanitas Gavazzeni; 🇮🇹 Milano, Italy

Istituto Europeo di Oncologia; 🇮🇹 Milano, Italy

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"; 🇮🇹 Meldola, Italy

Istituti Clinici Scientifici Maugeri; 🇮🇹 Pavia, Italy

Azienda USL IRCCS Di Reggio Emilia - Maria Nuova; 🇮🇹 Reggio Emilia, Italy

San Maria della Misericordia Hospital; 🇮🇹 Perugia, Italy